Galectin Therapeutics Inc (GALT) stock
GALTNasdaqPharmaceutical PreparationsFiscal year ends December 31
$2.91−0.11 (-3.64%)
Close on Nov 17, 2026Market cap $293.47MP/E –Yield –
Galectin Therapeutics enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
Galectin Therapeutics's enterprise value was $204.90M on Nov 11, 2026, against $357.90M a year earlier. Over the last 5 years it ranged from $45.01M to $358.42M, with a median of $103.58M.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | $204.90M | -20.2% |
| 2025 | Dec 31, 2025 | $256.68M | +381.4% |
| 2024 | Dec 31, 2024 | $53.32M | -35.2% |
| 2023 | Dec 29, 2023 | $82.31M | +60.4% |
| 2022 | Dec 30, 2022 | $51.32M | -40.5% |
| 2021 | Dec 31, 2021 | $86.24M | -9.5% |
| 2020 | Dec 31, 2020 | $95.30M | -14.7% |
| 2019 | Dec 31, 2019 | $111.71M | -14.7% |
| 2018 | Dec 31, 2018 | $130.96M | +16.9% |
| 2017 | Dec 29, 2017 | $112.08M | +779.4% |
| 2016 | Dec 30, 2016 | $12.74M | -28.9% |
| 2015 | Dec 31, 2015 | $17.92M | -60.7% |
| 2014 | Dec 31, 2014 | $45.57M | -65.7% |
| 2013 | Dec 31, 2013 | $132.90M | +513.3% |
| 2012 | Dec 31, 2012 | $21.67M | -67.1% |
| 2011 | Dec 30, 2011 | $65.89M | – |
See a number that looks wrong?